Skip to content

AIM-HI Accelerator Fund bridges the gap between innovative, early-stage cancer research and successful development of high-impact oncology products. Our integrated approach combines essential funding with development and business expertise, leading to successful oncology companies that bring forth new biomedical discoveries that create value and benefit society.

AIM-HI Accelerator Fund has built a powerful network that aims to provide critically needed support for their portfolio of startups and engages a careful strategy to de-risk its portfolio companies. AIM-HI Accelerator Fund provides the following support and access to its portfolio companies:

1. Portfolio Review Meetings:

Interact with the key opinion leaders in cancer research and clinical development experts, business leaders, successful serial entrepreneurs, SBIR partners, and venture investors for valuable insights on their clinical and business development plans.

2. Workshops and Panels:

Provide access to AIM-HI’s partners network of non-profit funding sources as well as family offices and venture capitalists interested in startup investments in biotech/pharmaceutical sectors.

3. Executives-in-Residence and Advisors:

  • Executive Mentoring: Assistance by C-level and founding big pharma executives in managing startups’ science and business development strategies, fundraising strategies, and ultimately, positioning for and executing exits.
  • Clinical Trial Design: Clinical trial design and trial placement assistance (poor trial design is a leading cause of failure for early-stage oncology startups.
  • Finance and Accounting: Experts in outsourcing tax, accounting, and legal (IP) support, as well as a centralized service for R&D tax credit filing (many startups do not file their 10% credit for R&D spending); this will ensure proper protection of AIM-HI investments and operating efficiency, while allowing the leadership team to focus on science, development, and marketing.
  • Contract Research Organizations: Introduction to vetted contract research organizations (CROs) with expertise in conducting intensive iterative aspects of research and development to pharma standards to minimize risk of having to repeat clinical research.
  • Regulatory Guidance: Evaluation of startup’s regulatory path guidance from experts experienced working with the FDA and other regulatory agencies.
  • International Legal Advisors: Introduction to leading international legal experts in early stage oncology companies to secure intellectual property and corporate legal and financial structures.
  • International Network Opportunities: meet and interact with leading scientists, non-profit and philanthropic venture funds, family offices, biotech investors, and pharmaceutical executives:
Back To Top